Sutro Biopharma and Ipsen Announce $900 Million Licensing Deal for STRO-003 ADC
On April 1, 2024, Sutro Biopharma, a NASDAQ-listed American company, and the renowned French pharmaceutical company Ipsen, entered into a global exclusive licensing agreement. The agreement covers Sutro's investigational ADC (Antibody-Drug Conjugate) candidate, STRO-003. Under the terms of the deal, Ipsen will make an upfront payment of $90 million to Sutro and potentially pay up to $900 million in milestone payments. This is Ipsen's first major investment in the ADC field.
STRO-003 is a next-generation ADC targeting ROR1 (Receptor Tyrosine Kinase-Like Orphan Receptor 1). This ADC uses exatecan (iexabepilone) as the payload, delivered through a β-glucuronidase-cleavable linker. In addition to STRO-003, Sutro has other ADC candidates in clinical development, including FRa ADC and CD74 ADC, as well as TF ADC in preclinical stages. The company is also collaborating with Astellas on immunostimulatory ADCs (iADCs) in preclinical research.
In the ROR1 ADC space, other notable candidates include CS5001 from LegoChem/Cornerstone, Zilovertamab Vedotin (MK-2140) from Merck/VelosBio, a bispecific antibody-drug conjugate from Bolt Biotherapeutics, and NBE-002 from BI/NBE Therapeutics. According to recent clinical data from Cornerstone, CS5001 has demonstrated promising anti-tumor activity and a favorable safety profile across various solid tumors and hematological malignancies.
This transaction not only highlights the immense potential of ADC technology in targeted cancer therapy, but also reflects the intense competition among domestic and international pharmaceutical companies in this field. A thorough analysis of the current clinical and market landscape of ROR1 ADCs will help us better understand the future development trends of innovative medicines.
2026-10-12
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Korea Unlocks Additive Flexibility: New Rules Broaden Food Ingredient Horizons
-
Japan Tightens Tap: Pesticide Limits in Drinking Water Get a Safety Overhaul
-
Uganda Sets Sugar Standards: East African Drafts Define Sweetness and Safety
-
Thailand Clears the Path for Vitamin Use: Streamlined Approval for Supplements
-
Solvay's "Slimming Action": Soda Ash Production Capacity in Spain Slashed by 180,000 Tons, 77 Jobs to Go
-
Wacker Under Global Cost Pressure: Dual-Track Restructuring Through Layoffs, Consolidation, and Strategic Repositioning
-
Saudi Aramco Weighs Discounts of Up to $9/Barrel on Oman STS Crude as Freight Costs Surge
-
Honeywell Acquires Johnson Matthey Catalyst Business at a Discount, Cutting £475 Million from the Price
-
India Swings the Tariff Axe at Made-in-China: Epoxy Resins Are Just the Beginning—The Road for Chinese Chemicals Abroad Is No Longer Smooth
-
Japan Begins Construction of the World’s Largest Commercial Liquid Hydrogen Receiving Terminal
Recommend Reading
-
UAE Breaks Ground on World’s First Gigascale Round-the-Clock Renewable Energy Project, Setting a New Global Standard For Clean Energy
-
“The 40-Year Ethylene Giant Collapses”: ExxonMobil’s Premature Shutdown Is Not Just Scotland’s Tragedy—It’s the Twilight Elegy of European Industrial Civilization
-
Sulfur Price Hits 7,633 CNY/Ton, Up Nearly Sixfold in a Year and a Half; Domestic Refining Giants Halt New Orders Due to Tight Supply
-
“Amputation or Strategic Retreat?”: Shell’s Six-Year Chemical Losses and the Quiet Unwinding of an Empire
-
Arkema and ENNEX Forge Global Alliance to Power the Next Generation of Safer, Smarter Battery Separators
-
Suppliers Hold Firm on Prices, Slight Increase in Butadiene Market in China
-
Supply-Demand Contradiction Persists, Making Weak ABS Market Conditions Hard to Reverse
-
Benzoylecgonine: Detection and Testing Methods
-
High Supply Remains Firm, Weakness in ABS Market Persists at End of October in China
-
Cost Side Rebounds, Polyester Staple Fiber Prices Rise Slightly